APVO on Nasdaq
Aptevo Therapeutics Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with TherapeuticsMD, Inc., Xenetic Biosciences (United States) or Upstream Bio, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2022
-919.7%Operating margin3
257.8%Net margin3
-74.7%Revenue growth, 20223
44.7%Return on equity4
0.08×Debt to equity3
-$21.1MFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2022
- Research and development69¢$17.9M
- Profit31¢$8.0M
Out of $3.1M in revenue.3
Financial statements
Every line of the income statement in the latest annual report, as filed.11
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | -$14.5M | -$14.4M |
| General and administrative | -$11.8M | -$10.2M |
| Loss from operations | -$26.3M | -$24.6M |
| Other income, net | $345.0K | $472.0K |
| Net loss | -$26.0M | -$24.1M |
| Dividend attributable to down round feature of warrants | -$1.6M | |
| Net loss attributable to common stockholders | -$27.5M | -$24.1M |
| Basic net loss per share | -$87.27 | -$31,460.23 |
| Diluted net loss per share | -$87.27 | -$31,460.23 |
| Basic shares used in calculation | 315.5K shares | 767 shares |
| Diluted shares used in calculation | 315.5K shares | 767 shares |
Every line of the balance sheet in the latest annual report, as filed.11
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $21.6M | $8.7M | |
| Prepaid expenses and other current assets | $1.5M | $1.9M | |
| Total current assets | $23.1M | $10.7M | |
| Property and equipment, net | $303.0K | $543.0K | |
| Operating lease right-of-use asset | $3.8M | $4.4M | |
| Total assets | $27.2M | $15.6M | |
| Accounts payable | $877.0K | $1.2M | |
| Accrued expenses and other current liabilities | $4.3M | $4.2M | |
| Operating lease liability, current portion | $866.0K | $768.0K | |
| Total current liabilities | $6.0M | $6.2M | |
| Operating lease liability, net of current portion | $3.8M | $4.6M | |
| Total liabilities | $9.8M | $10.8M | |
| Common stock: $0.001 par value; 500,000,000 shares authorized; 997,830 and 4,051 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $114.0K | $84.0K | |
| Additional paid-in capital | $292.4M | $252.2M | |
| Accumulated deficit | -$275.1M | -$247.6M | |
| Total stockholders' equity | $17.4M | $4.8M | $12.2M |
| Total liabilities and stockholders' equity | $27.2M | $15.6M | |
| Preferred stock, par value | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 15.0M shares | 15.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Common stock, par value | $0.00 | $0.00 | |
| Common stock, shares authorized | 500.0M shares | 500.0M shares | |
| Common stock, shares issued | 997.8K shares | 4.1K shares | |
| Common stock, shares outstanding | 997.8K shares | 4.1K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.11
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$26.0M | -$24.1M |
| Stock-based compensation | $96.0K | $1.1M |
| Non-cash lease expense | $1.1M | $1.1M |
| Depreciation and amortization | $240.0K | $352.0K |
| Prepaid expenses and other current assets | $483.0K | $217.0K |
| Accounts payable, accrued compensation, accrued expenses and other current liabilities, and short-term operating lease | -$157.0K | -$1.0M |
| Operating lease liability | -$1.4M | -$1.4M |
| Net cash used in operating activities | -$25.6M | -$23.8M |
| Net cash from investing activities | $0 | $0 |
| Value of equity awards withheld for tax liability | $0 | -$1.0K |
| Proceeds from exercise of common warrants, net of issuance costs | $557.0K | $5.6M |
| Proceeds from issuance of common stock, pre-funded warrants exercise, and common warrants exercise, net of issuance costs | $37.9M | $10.0M |
| Payments in lieu of fractional shares | -$3.0K | |
| Net cash provided by financing activities | $38.5M | $15.6M |
| Increase (decrease) in cash and cash equivalents | $12.9M | -$8.2M |
| Warrant modification - incremental value | $586.0K | $472.0K |
| Dividend attributable to down round feature of warrants | $1.6M | |
| Fair value of December 2024 inducement transaction common warrants | $7.3M |
Recent filings
- Oct 14, 20268-K
- Sep 25, 2026S-8
- Sep 24, 20268-K
- Sep 23, 20268-K
- Sep 3, 20268-K
- Sep 3, 2026424B4
- Sep 2, 2026EFFECT
- Aug 31, 2026DEF 14A
- Aug 26, 2026D
- Aug 21, 20268-K
- Aug 21, 2026S-1
- Aug 21, 2026PRE 14A
- Aug 14, 20268-K
- Aug 14, 202610-Q
- Aug 14, 2026SCHEDULE 13G/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11